CluenexSolventum SOLV
Solventum scores weak on business quality (3.4 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Solventum does
Solventum provides healthcare supplies, medical surgical products, and health information systems, selling directly to hospitals, clinics, and payors. The business focuses on carving out its operations as an independent entity to streamline product delivery and cut overhead.
- What it does best
Solventum generates a strong return on equity of 29.0%, outperforming peers like MDLN at 5.5%. This profitability stems from deeply embedded hospital supply contracts and proprietary medical tech that clinicians rely on daily.
- The main risk
High debt loads leave little room for operational error, with total debt at $5.0B and interest coverage sitting thin at 2.3x. If cash generation fails to recover from recent negative free cash flow of -$116M, debt servicing will strain core operations.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins rest at 7.3%, lagging behind peer LNTH at 20.2%. Free cash flow margin sits at negative 1.4%, meaning the business currently burns cash as it scales.
Solventum relies on entrenched hospital relationships and sticky medical device product lines, reflected in a top-decile ROE of 29.0%. Rivals face high switching costs in clinical settings.
Revenue grew just 0.9% to $8.3B, lagging far behind sector norms in the bottom quartile. Top-line expansion remains nearly stagnant compared to prior years.
Total debt sits at $5.0B against $878M in cash, while interest coverage of 2.3x leaves little cushion. Free cash flow dropped to -$116M from $805M previously, showing a softer balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on SOLV
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Solventum scores weak on the Cluenex quality check (3.4 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 5, 2026.
See SOLV today
- Today's verdict on SOLV, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Solventum (SOLV)”, https://cluenex.com/stocks/solv/, data as of Oct 10, 2026.